WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317331

CAS#: 147536-97-8 (free)

Description: Bosentan is a mixed Endothelin Receptor Antagonist which is used as a vasodilator. Bosentan is an inhibitor of ETAR and ETBR. It is used for the treatment of pulmonary artery hypertension (PAH). Bosentan blocks the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.

Chemical Structure

CAS# 147536-97-8 (free)

Theoretical Analysis

MedKoo Cat#: 317331
Name: Bosentan
CAS#: 147536-97-8 (free)
Chemical Formula: C27H29N5O6S
Exact Mass: 551.18385
Molecular Weight: 551.61
Elemental Analysis: C, 58.79; H, 5.30; N, 12.70; O, 17.40; S, 5.81

Price and Availability

Size Price Availability Quantity
10.0mg USD 180.0 2 Weeks
50.0mg USD 490.0 2 Weeks
Bulk inquiry

Related CAS #: 147536-97-8 (Bosentan free)   157212-55-0 (Bosentan hydrate)    

Synonym: Bosentan; bosentan anhydrous; bosentan monohydrate; Ro 47-0203; Ro-47-0203; Tracleer; Ro-47-0203.

IUPAC/Chemical Name: 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide


InChi Code: InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Certificate of Analysis:

Safety Data Sheet (SDS):

Preparing Stock Solutions

The following data is based on the product molecular weight 551.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Joyeux-Faure M, Jullian-Desayes I, Pepin JL, Cracowski JL, Baguet JP, Tamisier
R, Levy P, Godin-Ribuot D, Launois SH. Comparison of continuous positive airway
pressure and bosentan effect in mildly hypertensive patients with obstructive
sleep apnoea: A randomized controlled pilot study. Respirology. 2015 Dec 8. doi:
10.1111/resp.12713. [Epub ahead of print] PubMed PMID: 26643404.

2: Bellando-Randone S, Lepri G, Bruni C, Blagojevic J, Radicati A, Cometi L, De
Paulis A, Matucci-Cerinic M, Guiducci S. Combination therapy with Bosentan and
Sildenafil improves Raynaud's phenomenon and fosters the recovery of
microvascular involvement in systemic sclerosis. Clin Rheumatol. 2015 Dec 3.
[Epub ahead of print] PubMed PMID: 26631100.

3: Avdeev SN. [Approaches to therapy for pulmonary hypertension: Role of the
endothelin receptor antagonist bosentan]. Ter Arkh. 2015;87(9):64-71. Russian.
PubMed PMID: 26591555.

4: Enderle Y, Meid AD, Friedrich J, Grünig E, Wilkens H, Haefeli WE, Burhenne J.
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan,
Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. Anal
Chem. 2015 Dec 3. [Epub ahead of print] PubMed PMID: 26583764.

5: Matsunaga N, Kaneko N, Staub AY, Nakanishi T, Nunoya K, Imawaka H, Tamai I.
Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan
Metabolites Based on a Quantitative Modeling of Metabolism and Transport in
Sandwich-Cultured Human Hepatocytes. Drug Metab Dispos. 2016 Jan;44(1):16-27.
doi: 10.1124/dmd.115.067074. Epub 2015 Oct 26. PubMed PMID: 26502773.

6: Zahedi A, Nematbakhsh M, Moeini M, Talebi A. Role of endothelin receptor
antagonist; bosentan in cisplatin-induced nephrotoxicity in ovariectomized
estradiol treated rats. J Nephropathol. 2015 Oct;4(4):134-40. doi:
10.12860/jnp.2015.25. Epub 2015 Oct 1. PubMed PMID: 26457261; PubMed Central
PMCID: PMC4596298.

7: Amin A, Mohamadifar A, Taghavi S, Naderi N, Sadeghi H. Lower Doses of Bosentan
in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial
Hypertension. Res Cardiovasc Med. 2015 Aug 1;4(3):e26487. doi:
10.5812/cardiovascmed.26487v2. eCollection 2015 Aug. PubMed PMID: 26436071;
PubMed Central PMCID: PMC4588707.

8: Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, Ivy DD, Jaïs X,
Miera O, Rosenzweig EB, Efficace M, Kusic-Pajic A, Beghetti M. FUTURE-2: Results
from an open-label, long-term safety and tolerability extension study using the
pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J
Cardiol. 2016 Jan 1;202:52-8. doi: 10.1016/j.ijcard.2015.08.080. Epub 2015 Aug 9.
PubMed PMID: 26386921.

9: Taquin H, Lacour JP, Le Duff F, Chiaverini C, Passeron T. Treatment of
resistant port-wine stains with bosentan and pulsed dye laser: a pilot
prospective study. J Eur Acad Dermatol Venereol. 2015 Aug 24. doi:
10.1111/jdv.13275. [Epub ahead of print] PubMed PMID: 26304141.

10: Masarwa R, Shamriz O, Zilkha A, Braun J, Kleid DM, Weintraub M, Schulz A,
Stepensky P. Bosentan-induced Reduction in Cyclosporine-A Levels: A Rare
Interaction in an Infant With Osteopetrosis and Severe Pulmonary Hyperetension. J
Pediatr Hematol Oncol. 2015 Oct;37(7):573-4. doi: 10.1097/MPH.0000000000000409.
PubMed PMID: 26274036.

11: Serafim KG, Navarro SA, Zarpelon AC, Pinho-Ribeiro FA, Fattori V, Cunha TM,
Alves-Filho JC, Cunha FQ, Casagrande R, Verri WA Jr. Bosentan, a mixed endothelin
receptor antagonist, inhibits superoxide anion-induced pain and inflammation in
mice. Naunyn Schmiedebergs Arch Pharmacol. 2015 Nov;388(11):1211-21. doi:
10.1007/s00210-015-1160-z. Epub 2015 Aug 6. PubMed PMID: 26246053.

12: Sebastiani M, Manfredi A, Cestelli V, Praino E, Cannarile F, Giuggioli D,
Colaci M, Ferri C. Validation study of predictive value of capillaroscopic skin
ulcer risk index (CSURI) in scleroderma patients treated with bosentan. Clin Exp
Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S196. Epub 2015 Aug 5. PubMed PMID:

13: Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, Studer R,
Vezzali E, Freti D, Hadana H, Schläpfer M, Cattaneo C, Bortolamiol C, Weber E,
Whitby BR, Delahaye S, Wanner D, Steiner P, Nayler O, Hess P, Clozel M.
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat
Model of Non-vasoreactive Pulmonary Hypertension. J Cardiovasc Pharmacol. 2015
Nov;66(5):457-67. doi: 10.1097/FJC.0000000000000296. PubMed PMID: 26230396;
PubMed Central PMCID: PMC4632117.

14: Sharabi I, Tanay A, Zandman-Goddard G. Digital Ulcers, Systemic Sclerosis
Sine Scleroderma and Paraneoplastic Phenomena Responding to Bosentan Therapy. Isr
Med Assoc J. 2015 Feb;17(2):126-7. PubMed PMID: 26223094.

15: Rotondo C, Praino E, Nivuori M, Di Serio F, Lapadula G, Iannone F. No changes
in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients
with systemic sclerosis-associated pulmonary arterial hypertension on therapy
with bosentan. Int J Rheum Dis. 2015 Jul 28. doi: 10.1111/1756-185X.12721. [Epub
ahead of print] PubMed PMID: 26218502.

16: McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, Souza
R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM. Bosentan added to
sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir
J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25.
PubMed PMID: 26113687.

17: Romano E, Bellando-Randone S, Manetti M, Bruni C, Lepri G, Matucci-Cerinic M,
Guiducci S. Bosentan blocks the antiangiogenic effects of sera from systemic
sclerosis patients: an in vitro study. Clin Exp Rheumatol. 2015 Jul-Aug;33(4
Suppl 91):S148-52. Epub 2015 Jun 19. PubMed PMID: 26088817.

18: Muraoka H, Imamura T, Hatano M, Maki H, Yao A, Kinugawa K, Komuro I. Secure
Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat
Portopulmonary Hypertension Minimizing Each Adverse Effect. Int Heart J.
2015;56(4):471-3. doi: 10.1536/ihj.15-007. Epub 2015 Jun 18. PubMed PMID:

19: Doganci S, Yildirim V, Yesildal F, Erol G, Kadan M, Ozkan G, Avcu F, Ozgurtas
T. Comparison of angiogenic and proliferative effects of three commonly used
agents for pulmonary artery hypertension (sildenafil, iloprost, bosentan): is
angiogenesis always beneficial? Eur Rev Med Pharmacol Sci. 2015
May;19(10):1900-6. PubMed PMID: 26044238.

20: Onda N, Tanaka Y, Hino M, Gemma A. Bosentan for pulmonary hypertension
secondary to idiopathic pulmonary fibrosis. Respir Med Case Rep. 2014 Dec
16;14:19-23. doi: 10.1016/j.rmcr.2014.11.008. eCollection 2015. PubMed PMID:
26029570; PubMed Central PMCID: PMC4356039.


10.0mg / USD 180.0

Additional Information

147536-97-8 (Bosentan free)
157212-55-0 (Bosentan hydrate).